IP Library Granted Patent US 11,919,935
Granted Patent B2
US 11,919,935 · App. 17/523,133 · Granted Mar 5, 2024

Ultra-long acting insulin-Fc fusion proteins and methods of use

Inventors: Thomas M. Lancaster (Wenham, MA); Todd C. Zion (Marblehead, MA)
Assignee: Akston Biosciences Corporation
C07K14/62C07H21/04C07K2319/30C07K2319/70C12N5/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,919,935
App. No.
17/523,133
Granted
Mar 5, 2024
Kind
B2
Abstract

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

Claims (108)

1. A recombinant cell comprising a nucleic acid encoding a fusion protein, said fusion protein comprising an insulin polypeptide and an Fc fragment, wherein the insulin polypeptide and the Fc fragment are connected by a linker, wherein the Fc fragment comprises the following sequence:

(SEQ ID NO: 32)

CPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTCVVVDLDPEDPEVQ

ISWFVDGKQMQTAKTQPREEQFKGTYRVVSVLPIGHQDWLKGKQFTCKV

NNKALPSPIERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLIKDF

FPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSRWQR

GDTFICAVMHEALHNHYTQESLSHSPG

and wherein the insulin polypeptide comprises the following sequence:

(SEQ ID NO: 16)

FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICSL

YQLENYCN.

2. The recombinant cell of claim 1 , wherein the cell is a HEK293 cell or a CHO cell.

3. The recombinant cell of claim 1 , wherein said nucleic acid comprises cDNA encoding said fusion protein, said fusion protein comprising the following sequence:

(SEQ ID NO: 51)

FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICSLY

QLENYCNGGGGAGGGGCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEV

TCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFKGTYRVVSVLPIG

HQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELS

KNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLY

SKLSVDKSRWQRGDTFICAVMHEALHNHYTQESLSHSPG.

4. The recombinant cell of claim 3 , wherein the cDNA comprises the following nucleic acid sequence:

(SEQ ID NO: 52)

atggaatggagctgggtctttctcttcttcctgtcagtaacgactggtgt

ccactccttcgtgaaccagcacctgtgcggctccgacctggtggaagctc

tggctctcgtgtgcggcgagcggggcttcttctacaccgatcccactgga

ggcggtccacgcagaggcatcgtggaacagtgctgccactccatctgctc

cctgtaccagctggaaaactactgcaatggcggaggtggtgcaggaggcg

gtggatgccccaagtgccccgctcccgagatgctgggcggacccagcgtg

ttcatcttccccccaagcccaaggacacactgctgatcgccaggaccccg

gaggtgacctgcgtggtggtggacctggatcccgaagaccccgaggtgca

gatcagctggttcgtggatggaaagcagatgcagaccgccaagacccaac

cccgggaagagcagttcaaaggcacctacagggtggtgagtgtgttgccc

atcggccaccaggactggctgaaggggaagcaattcacatgcaaggttaa

taacaaggccctgcccagccccatcgagaggaccatcagcaaggccaggg

gccaggcccaccagccatctgtgtacgtgctgcccccatctagggaggaa

ctgagcaagaacacagtcagccttacttgcctgatcaaggacttcttccc

accggacatagacgtggagtggcagagtaacggccagcaggagcccgaga

gcaagtataggaccacaccgccccaactggacgaggacggaagctacttc

ctctacagcaaattgagcgttgacaaaagcaggtggcagcgaggcgacac

cttcatctgcgccgtgatgcacgaggctttgcataaccactacacccagg

agagcctgtcccacagccccggatag.

5. The recombinant cell of claim 1 , wherein said recombinant cell is a stably transfected recombinant cell.

6. A method of preparing a recombinant cell according to claim 1 , said method comprising:

transfecting a host cell with a nucleic acid encoding for said fusion protein comprising said insulin polypeptide and said Fc fragment connected by said linker, wherein said fusion protein is expressed in said recombinant cell after said transfecting step.

7. The method of claim 6 , further comprising:

culturing said recombinant cell in cell culture media; and harvesting cell culture supernatant from said cell culture media, said cell culture supernatant comprising said expressed fusion protein.

8. The method of claim 7 , further comprising:

recovering said fusion protein from said cell culture supernatant.

9. The method of claim 8 , wherein said recovering step comprises one or more steps of centrifugation, filtration, or chromatography.

10. The method of claim 6 , wherein said transfecting step comprises stable transfection of said host cell.

11. The method of claim 6 , wherein said nucleic acid comprises cDNA encoding said fusion protein, said fusion protein comprising the following sequence:

(SEQ ID NO: 51)

FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICSLY

QLENYCNGGGGAGGGGCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEV

TCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFKGTYRVVSVLPIG

HQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELS

KNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLY

SKLSVDKSRWQRGDTFICAVMHEALHNHYTQESLSHSPG.

12. The method of claim 11 , wherein the cDNA comprises the following nucleic acid sequence:

(SEQ ID NO: 52)

atggaatggagctgggtctttctcttcttcctgtcagtaacgactggtgt

ccactccttcgtgaaccagcacctgtgcggctccgacctggtggaagctc

tggctctcgtgtgcggcgagcggggcttcttctacaccgatcccactgga

ggcggtccacgcagaggcatcgtggaacagtgctgccactccatctgctc

cctgtaccagctggaaaactactgcaatggcggaggtggtgcaggaggcg

gtggatgccccaagtgccccgctcccgagatgctgggcggacccagcgtg

ttcatcttccctcccaagcccaaggacacactgctgatcgccaggacccc

ggaggtgacctgcgtggtggtggacctggatcccgaagaccccgaggtgc

agatcagctggttcgtggatggaaagcagatgcagaccgccaagacccaa

ccccgggaagagcagttcaaaggcacctacagggtggtgagtgtgttgcc

catcggccaccaggactggctgaaggggaagcaattcacatgcaaggtta

ataacaaggccctgcccagccccatcgagaggaccatcagcaaggccagg

ggccaggcccaccagccatctgtgtacgtgctgcccccatctagggagga

actgagcaagaacacagtcagccttacttgcctgatcaaggacttcttcc

caccggacatagacgtggagtggcagagtaacggccagcaggagcccgag

agcaagtataggaccacaccgccccaactggacgaggacggaagctactt

cctctacagcaaattgagcgttgacaaaagcaggtggcagcgaggcgaca

ccttcatctgcgccgtgatgcacgaggctttgcataaccactacacccag

gagagcctgtcccacagccccggatag.

13. A cDNA encoding a fusion protein comprising the following sequence:

(SEQ ID NO: 51)

FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICSLY

QLENYCNGGGGAGGGGCPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEV

TCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFKGTYRVVSVLPIG

HQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELS

KNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLY

SKLSVDKSRWQRGDTFICAVMHEALHNHYTQESLSHSPG.

14. The cDNA of claim 13 , wherein the cDNA comprises the following nucleic acid sequence:

(SEQ ID NO: 52)

atggaatggagctgggtctttctcttcttcctgtcagtaacgactggtgt

ccactccttcgtgaaccagcacctgtgcggctccgacctggtggaagctc

tggctctcgtgtgcggcgagcggggcttcttctacaccgatcccactgga

ggcggtccacgcagaggcatcgtggaacagtgctgccactccatctgctc

cctgtaccagctggaaaactactgcaatggcggaggtggtgcaggaggcg

gtggatgccccaagtgccccgctcccgagatgctgggcggacccagcgtg

ttcatcttccctcccaagcccaaggacacactgctgatcgccaggacccc

ggaggtgacctgcgtggtggtggacctggatcccgaagaccccgaggtgc

agatcagctggttcgtggatggaaagcagatgcagaccgccaagacccaa

ccccgggaagagcagttcaaaggcacctacagggtggtgagtgtgttgcc

catcggccaccaggactggctgaaggggaagcaattcacatgcaaggtta

ataacaaggccctgcccagccccatcgagaggaccatcagcaaggccagg

ggccaggcccaccagccatctgtgtacgtgctgcccccatctagggagga

actgagcaagaacacagtcagccttacttgcctgatcaaggacttcttcc

caccggacatagacgtggagtggcagagtaacggccagcaggagcccgag

agcaagtataggaccacaccgccccaactggacgaggacggaagctactt

cctctacagcaaattgagcgttgacaaaagcaggtggcagcgaggcgaca

ccttcatctgcgccgtgatgcacgaggctttgcataaccactacacccag

gagagcctgtcccacagccccggatag.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2024
From: AKSTON BIOSCIENCES CORPORATION
To: DECHRA LIMITED
Reel/Frame 068600/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2021
From: LANCASTER, THOMAS M.; ZION, TODD C.
To: AKSTON BIOSCIENCES CORPORATION
Reel/Frame 058137/0812 →